Greater buy-in to these services by GPs could persuade more patients to participate, and further

work is required to explore patient perceptions of these schemes as well as reasons why more patients are not recruited to NMS or MURs. 1. Sexton J, Ho, YJ, Green, CF and Caldwell, NA. Ensuring seamless care at hospital discharge: A national survey. Journal of Clinical Pharmacy and Therapeutics, 2000; 25: 385–393 R. Millera,b, C. Darcya, A. Friela, M. Scottc, S. Tonerc aWestern Health and Social Care Trust, Derry, Northern Ireland, UK, bUniversity of Ulster, Coleraine, Northern Ireland, UK, cNorthern Health and Social Care Trust, Antrim, Northern Ireland, UK The project objective was to implement and evaluate consultant pharmacist (CP) case management of older people within intermediate care (IC) and back out into primary care. Over a 12-month period 453 patients were Dabrafenib molecular weight case managed. Data on clinical interventions, medication appropriateness, drug costs and patient outcomes were collected and evaluated. CP case management for older people in IC demonstrated a cost- effective Ibrutinib order patient-centred model of pharmaceutical care which could be replicated in similar settings. In December 2011, the Compton Review ‘Transforming

Your Care’ outlined the remodelling of Health and Social Care in Northern Ireland (HSCNI), specifically recommending better integration of hospital and community services for older people. The consultant pharmacist is an integral part of the health care model addressing the complex medicines management needs of the frail elderly. The objective of this project was to develop, implement and robustly evaluate a CP led PRKD3 case management pharmaceutical

care service for older patients admitted to intermediate care and continued back into the community setting. Prior to project initiation (May 2012), a multidisciplinary process mapping event was held informing development of the new patient care pathway where the CP case managed patients (≥ 65 years) throughout their stay in IC and for at least 30 days post-discharge. The trust research governance committee decided this project was service improvement and evaluation not requiring governance or ethical approvals. On admission to the IC hospital, the CP reviewed appropriateness of drugs prescribed using the Medication Appropriateness Index (MAI). Patient-specific pharmaceutical care plans were implemented with clinical interventions being recorded and graded according to Eadon criteria.1 Costs savings as a result of these interventions which prevent medication errors/Adverse Drug Events (ADEs) have been estimated by the University of Sheffield School of Health and Related Research (ScHARR)2; these figures were applied. Drugs stopped/started by the CP were costed using the NHS dictionary of medicines and devices (DM&D).